

Evaluating sequencing strategies for ATMP genomic risk assessment

Rafaella Buzatu

Prof. Micha Drukker

Asst. Prof. Christian Schröter

Tineke van den Hoorn

Marcel Hoefnagel




Universiteit
Leiden


$\frac{C \ B \ G}{M \ E \ B}$

Advanced Therapeutic Medicinal Products (ATMPs)

Somatic cell
therapies




Tissue engineered
medicines




Gene therapy
medicines




Combined ATMPs




iPSCs




iPSC-derived ATMPs are actively being tested in clinical trials



The iPSC starting material and final ATMP undergo rigorous safety assessment



Genomic variants can occur in iPSCs during reprogramming and culturing




Standards for genomic safety assessment are actively being established

- (S.3.1) “**Genetic stability** should be evaluated for cell preparations that undergo extensive in vitro manipulation **using orthogonal methods**. When relevant, **cross reference to tumorigenicity studies in the non-clinical part** of the dossier can be made.” ¹
- (Recommendation 3.2.2.5) “Culture-acquired genetic abnormalities may be a significant risk and **should be part of in process and/or final product testing** for stem cell products that have undergone extensive expansion in vitro.” ²



***Goal:** Quantify information from NGS strategies (WGS, WES, RNAseq) relevant for safety assessment of ATMPs*

Next-generation sequencing allows large-scale sequencing of cell products






Sequencing of product


NGS Workflow




Sequencing of product




Genomic risk assessment includes variant calling and interpretation




Sequencing methods differ in output




WGS uniformly covers the entire genome




Exome sequencing enriches exonic regions through probe hybridization




RNAseq captures mature mRNAs through poly(A) tail capture




RNAseq also reveals gene expression patterns that define cell identity




DNA and RNA-based sequencing reads are aligned with different methodologies




NGS displays a high number of low-coverage positions that are excluded





RNAseq data is enriched in exonic regions compared with ExomeSeq




Exon coverage is similar between RNAseq and exomeSeq




RNAseq reliably captures more cancer gene exons than exomeSeq




RNAseq and ExomeSeq cover different coding regions





Variant calling is performed using the same software




Small variant overlap between genomics and transcriptomics methods





RNAseq captures 23% of WGS variants, while exomeSeq only 18%




19% of variants captured using RNAseq are specific to this method




RNAseq-unique variant positions are covered in WGS but not in exomeSeq




Over 90% of RNAseq-specific variants are not confirmed by WGS




RNAseq-unique variants supported in WGS




Not supported (ALT DP = 0)



RNA editing can be detected by RNAseq, not by DNA-based sequencing methods




The rate of variation for different base changes is similar among methods




92% of variants unique to RNA follow RNA editing patterns

RNAseq-unique variants
supported in WGS




92% of variants unique to RNA follow RNA editing patterns


RNAseq-unique variants
supported in WGS



Variants unique to RNA



Take home messages



Take home messages


RNAseq

Cell identity



- Endoneurial fibroblast
- Mechanoreceptor
- Neural crest cell
- Nociceptor
- Proprioceptor
- Schwann cell




Variant detection




Take home messages

- RNAseq has a **higher relative focus on coding regions** that exomeSeq


RNAseq




Take home messages




- RNAseq has a **higher relative focus on coding regions** that exomeSeq
- RNAseq and exomeSeq **share coverage over only ~50%** of their respective regions




Take home messages




- RNAseq has a **higher relative focus on coding regions** that exomeSeq
- RNAseq and exomeSeq **share coverage over only ~50%** of their respective regions
- RNAseq captures **23 % of WGS coding variants**



Take home messages



- RNAseq has a **higher relative focus on coding regions** that exomeSeq
- RNAseq and exomeSeq **share coverage over only ~50%** of their respective regions
- RNAseq captures **23 % of WGS coding variants**
- The genomic variants captured by RNAseq that cannot be recapitulated in WGS are likely **RNA editing events**



Acknowledgements



Universiteit
Leiden

Prof. Micha Drukker, PhD

Christian Schröter, PhD

Andreea Iosif, MSc

Daan Vlemmings, Ir.

Cecile Herbermann, BSc

Nina Schulten, MSc

Jingchao Wu, PhD

Max Fernkorn, PhD

Benjamin Tak, MSc

Yuting Wang, MSc

Ruben de Vries, MSc

Eliane Züger, MSc

Joey Zuijdervelt, MSc

Yubin Guo, MSc

Ferdinand Teichert, Dr.
Med. Univ.

$\frac{c}{M} \frac{B}{E} \frac{G}{B}$

Tineke van den Hoorn, PhD


Marcel Hoefnagel, PhD



 drukkerlab.nl

Extra: Unique Molecular Identifiers (UMIs) tag each sequence in a sample library

PCR duplicate removal **without** UMIs



in silico
reduced to
1 molecule


PCR duplicate removal **with** UMIs




in silico reduced
to correct 3
molecules

Extra slide: Variant calling using UMIs allows detection of sequencing errors

Variant calling **without** UMIs




Variant calling **with** UMIs




Extra slide: Variant overlap between the three methods

Intronic variants



Exonic variants



Variants outside genes

